# 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

> **NCT07044310** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 38 (estimated)

## Conditions studied

- Anatomic Stage 0 Breast Cancer AJCC v8
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Hormone Receptor-Positive Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Mineral Density Test
- **OTHER:** Questionnaire Administration
- **DRUG:** WBF-038

## Key facts

- **NCT ID:** NCT07044310
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-07-25
- **Final completion:** 2027-07-25
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044310, "5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07044310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*